News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Hagop Kantarjian: Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia
Photo of Hagop Kantarjian from mdanderson.org
Jan 18, 2024, 11:27

Hagop Kantarjian: Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia

Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared on X:

“Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia (R/R ALL). Study now amended to add navitoclax (BCL-xL inhibitor).”

Hagop Kantarjian: Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia

Read further.
Source: Hagop Kantarjian/X

 

Acute Lymphoblastic Leukemia BCL-XL inhibitor cancer Hagop Kantarjian MD Anderson Cancer Center navitoclax OncoDaily Oncology venetoclax
Special Coverage
Blog
Dec 19, 2024, 02:54
Bladder-Sparing Strategies for MIBC: Insights from Professor Ming Cao at ESMO Asia2024
Blog
Dec 19, 2024, 02:52
Vicki Kennedy: The critical importance of psychosocial oncology standards
Blog
Dec 19, 2024, 02:47
Liver cancer treatment through radioembolization - IMAGIO
Blog
Dec 19, 2024, 02:43
Paolo Tarantino: The highly awaited Breast Cancer trials with positive results
Blog
Dec 19, 2024, 02:34
Javier Muñoz Carrillo: First-hand presentation of cutting-edge clinical trial results in breast cancer research at SABCS24
Science
Dec 19, 2024, 02:31
Laura Bukavina: Use of Perioperative Immunotherapy and TKI in RCC with IVC thrombus patients by Kotaro Suzuki et al.
Science
Dec 19, 2024, 02:26
Nicholas Hornstein: CtDNA for Appendiceal Adenocarcinoma is not as robust as in Colorectal Cancer
Blog
Dec 19, 2024, 02:20
Sathgen Therapeutics Named Company of the Year 2024 by Silicon India Magazine
Blog
Dec 19, 2024, 02:19
Cancer costs the average patient in Canada nearly $33,000 in their lifetime - Canadian Cancer Society
Blog
Dec 19, 2024, 02:17
Living with Blood Cancer makes time precious and more urgent - The Leukemia and Lymphoma Society
Blog
Dec 19, 2024, 02:16
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research - NCI Division of Cancer Prevention
Blog
Dec 19, 2024, 02:11
An upcoming FDA-AACR workshop on DPD deficiency testing